c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma

Author:

Singh Kamini1,Lin Jianan23ORCID,Zhong Yi4,Burčul Antonija4,Mohan Prathibha1,Jiang Man1,Sun Liping5,Yong-Gonzalez Vladimir6,Viale Agnes5,Cross Justin R.6,Hendrickson Ronald C.7,Rätsch Gunnar48,Ouyang Zhengqing29,Wendel Hans-Guido1ORCID

Affiliation:

1. Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY

2. The Jackson Laboratory for Genomic Medicine, Farmington, CT

3. Department of Biomedical Engineering, University of Connecticut, Storrs, CT

4. Computational Biology Department, Memorial Sloan Kettering Cancer Center, New York, NY

5. Integrated Genomics Operation, Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

6. Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY

7. Proteomics and Microchemistry, Memorial Sloan- Kettering Cancer Center, New York, NY

8. Biomedical Informatics, Department of Computer Science, Swiss Federal Institute of Technology, Zürich, Switzerland

9. Department of Genetics and Genome Sciences and Institute for System Genomics, University of Connecticut Health Center, Farmington, CT

Abstract

The oncogenic c-MYC (MYC) transcription factor has broad effects on gene expression and cell behavior. We show that MYC alters the efficiency and quality of mRNA translation into functional proteins. Specifically, MYC drives the translation of most protein components of the electron transport chain in lymphoma cells, and many of these effects are independent from proliferation. Specific interactions of MYC-sensitive RNA-binding proteins (e.g., SRSF1/RBM42) with 5′UTR sequence motifs mediate many of these changes. Moreover, we observe a striking shift in translation initiation site usage. For example, in low-MYC conditions, lymphoma cells initiate translation of the CD19 mRNA from a site in exon 5. This results in the truncation of all extracellular CD19 domains and facilitates escape from CD19-directed CAR-T cell therapy. Together, our findings reveal MYC effects on the translation of key metabolic enzymes and immune receptors in lymphoma cells.

Funder

National Institutes of Health

Center for Experimental Therapeutics at

Memorial Sloan Kettering Cancer Center

Lymphoma Research Foundation

Starr Cancer Consortium

Geoffrey Beene Cancer Research Center

Leukemia and Lymphoma Society

Specialized Center of Research

New York State Stem Cell Science

Sloan Kettering Institute

Swiss Federal Institute of Technology

National Institute of General Medical Sciences

National Cancer Institute

Cycle for Survival

Marie-Josée and Henry R. Kravis Center for Molecular Oncology

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3